Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, James Chih-Hsin, Wu, Yi-Long, Schuler, Martin · The Lancet Oncology · 2015